Competitive Rivalry

SIGA competes in a narrow biodefense market with limited approved-product overlap, so rivalry is structurally lower than in broad pharmaceutical categories.

Peer competition is muted because procurement is episodic and government-driven, which reduces continuous price undercutting versus diversified vaccine and antiviral peers.

Rivalry remains meaningful because BARDA and DoD purchasing cycles can shift volume between suppliers, but SIGA’s niche positioning limits direct head-to-head pressure.

Threat Of New Entrants

Regulatory, clinical, and manufacturing barriers are high in biodefense, making new entry slower and costlier than in many specialty-drug peer markets.

Government procurement qualification and stockpile requirements create long lead times, which protect incumbents like SIGA more than smaller emerging peers.

The market’s narrow demand base discourages entrants because fixed development costs are difficult to recover without durable federal contracts.

Bargaining Power Of Suppliers

SIGA’s supplier power is moderated by contract manufacturing and standard inputs, but limited production scale can leave it less diversified than larger global peers.

Specialized biodefense quality requirements can narrow the supplier pool, creating some margin pressure if capacity or compliance costs rise.

Compared with large pharmaceutical peers, SIGA has less purchasing leverage, though supplier constraints are not typically the primary driver of profitability.

Bargaining Power Of Buyers

The U.S. government is the dominant buyer, and concentrated procurement gives it stronger negotiating leverage than diversified commercial pharma customers.

Budget timing and stockpile policy can materially affect pricing and order size, limiting SIGA’s ability to reprice versus peers with broader end markets.

Buyer power is partly offset by the absence of close substitutes and the strategic nature of biodefense procurement, which prevents fully elastic pricing.

Threat Of Substitutes

Substitution risk is constrained because SIGA’s core products address specific biodefense use cases where therapeutic alternatives are limited or non-equivalent.

Broader antiviral or supportive-care options are not direct substitutes in stockpile procurement, preserving pricing power relative to mainstream infectious-disease peers.

The main substitute threat is policy-driven portfolio replacement by government buyers, but that is slower and less immediate than commercial therapeutic substitution.

Overall Score

SIGA’s industry structure is favorable versus global peers because entry barriers and limited substitutes support pricing power, while government buyer concentration remains the main structural constraint.